Citigroup Inc Amylyx Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 575,005 shares of AMLX stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

575,005

Previous 663,376 13.32%

Holding current value

$2.33 Million

Previous $1.26 Million 47.86%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.65 - $3.24 $145,812 - $286,322	-88,371 Reduced 13.32%	575,005 $1.86 Million
Q2 2024 Aug 12, 2024	SELL	$1.62 - $2.71 $407,188 - $681,161	-251,351 Reduced 27.48%	663,376 $1.26 Million
Q1 2024 May 10, 2024	BUY	$2.71 - $19.57 $1.43 Million - $10.3 Million	527,063 Added 135.96%	914,727 $2.6 Million
Q4 2023 Feb 09, 2024	BUY	$12.07 - $18.46 $4.15 Million - $6.35 Million	343,875 Added 785.3%	387,664 $5.71 Million
Q3 2023 Nov 09, 2023	SELL	$18.08 - $23.45 $610,742 - $792,141	-33,780 Reduced 43.55%	43,789 $801,000
Q2 2023 Aug 10, 2023	BUY	$20.98 - $31.42 $932,414 - $1.4 Million	44,443 Added 134.16%	77,569 $1.67 Million
Q1 2023 May 11, 2023	BUY	$27.71 - $40.93 $648,497 - $957,884	23,403 Added 240.7%	33,126 $971,000
Q4 2022 Feb 09, 2023	BUY	$29.75 - $39.26 $29,809 - $39,338	1,002 Added 11.49%	9,723 $359,000
Q3 2022 Nov 10, 2022	BUY	$17.15 - $30.92 $135,244 - $243,835	7,886 Added 944.43%	8,721 $245,000
Q2 2022 Aug 10, 2022	SELL	$6.85 - $19.93 $2,185 - $6,357	-319 Reduced 27.64%	835 $16,000
Q1 2022 May 12, 2022	BUY	$12.85 - $32.9 $14,828 - $37,966	1,154 New	1,154 $15,000

Others Institutions Holding AMLX

# of Institutions

127

Shares Held

44.4M

Call Options Held

235K

Put Options Held

530K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $237M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account